Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes

ADVANCE Collaborative Grp; Jun, Min; Harris, Katie; Heerspink, Hiddo J. L.; Badve, Sunil V.; Jardine, Meg J.; Harrap, Stephen; Hamet, Pavel; Marre, Michel; Poulter, Neil

[Link to publication in University of Groningen/UMCG research database](#)

IT'S NOT WILLPOWER
IT'S BIOLOGY

IT'S ONLY NATURAL FOR PATIENTS TO
FALL BACK INTO
WEIGHT REGAIN

Get the tools to help your patients stop falling back into excess weight.

Rethink Obesity®

BRIEF REPORT

WILEY

Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

Min Jun PhD[1,2] | Katie Harris PhD[1] | Hiddo J. L. Heerspink PhD[1,3] |
Sunil V. Badve PhD[1] | Meg J. Jardine PhD[4] | Stephen Harrap PhD[5] |
Pavel Hamet PhD[6] | Michel Marre PhD[7,8,9] | Neil Poulter PhD[10] |
Sradha Kotwal PhD[1] | Martin Gallagher PhD[1] | Vlado Perkovic PhD[1,2] |
John Chalmers PhD[1] | Mark Woodward PhD[1,11,12] | ADVANCE Collaborative Group

[1]The George Institute for Global Health, University of New South Wales, Sydney, New South Wales, Australia

[2]Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia

[3]Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, Groningen, the Netherlands

[4]NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia

[5]Department of Physiology, Royal Melbourne Hospital, University of Melbourne, Melbourne, Victoria, Australia

[6]Center de Rechercher, Center Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada

[7]INSERM, UMR S1138, Centre de Recherche des Cordeliers, Paris, France

[8]Department of Diabetology, Endocrinology and Nutrition, Assistance Publique-Hôpitaux de Paris, Bichat Hospital, DHU FIRE, Paris, France

[9]Université Paris Diderot, Sorbonne Paris Cité, UFR de Médecine, Paris, France

[10]International Centre for Circulatory Health, Imperial College, London, UK

[11]The George Institute for Global Health, School of Public Health, Imperial College, London, UK

[12]Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins University, Baltimore,, Maryland

Correspondence
Min Jun, PhD, The George Institute for Global Health, University of New South Wales, Sydney, Australia, Level 5, 1 King Street, Newtown, Sydney NSW 2042, Australia.
Email: mjun@georgeinstitute.org.au

Abstract

There are limited data on whether estimated glomerular filtration rate (eGFR) variability modifies the risk of future clinical outcomes in type 2 diabetes (T2D). We assessed the association between 20-month eGFR variability and the risk of major clinical outcomes in T2D among 8241 participants in the ADVANCE trial. Variability in eGFR (coefficient of variation [CV_{eGFR}]) was calculated from three serum creatinine measurements over 20 months. Participants were classified into three groups by thirds of CV_{eGFR}: low (≤ 6.4; reference), moderate (>6.4 to ≤ 12.1) and high (>12.1). The primary outcome was the composite of major macrovascular events, new or worsening nephropathy and all-cause mortality. Cox regression models were used to estimate hazard ratios (HRs). Over a median follow-up of 2.9 years following the 20-month period, 932 (11.3%) primary outcomes were recorded. Compared with low variability, greater 20-month eGFR variability was independently associated with higher risk of the primary outcome (HR for moderate and high variability: 1.07, 95% CI: 0.91–1.27 and 1.22, 95% CI: 1.03–1.45, respectively) with evidence of a positive linear trend (p = .015). These data

indicate that eGFR variability predict changes in the risk of major clinical outcomes in T2D.

KEYWORDS
diabetic nephropathy

1 | INTRODUCTION

Diabetes is the leading cause of chronic kidney disease (CKD).[1] People with diabetic kidney disease are at an increased risk of poor outcomes including end-stage kidney disease and cardiovascular disease.[2] Monitoring disease progression and the possibility of future adverse events is thus a cornerstone of the management of this high-risk group.[3] Routine assessment of estimated glomerular filtration rate (eGFR) is an important component of this management strategy.

One frequently observed occurrence in such routine outpatient assessments is within-person fluctuations in eGFR. However, whether this variation modifies the risk of clinical outcomes and death, or is non-consequential physiological variation, in people with type 2 diabetes (T2D), remains uncertain. A small number of studies to date have reported a higher risk of adverse kidney outcomes and all-cause death associated with greater eGFR variability.[4,5] However, these have been limited by narrow inclusion criteria: studying mostly men[4] and/or people with lower eGFR (<60 mL/min/1.73m^2).[1] An assessment of the clinical significance of eGFR variability in broader high-risk groups including T2D is needed.

Using data from the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE), a randomized controlled trial (RCT) in patients with T2D,[6-8] we assessed the relationships between 20-month variability in eGFR and major macrovascular events, new or worsening nephropathy events, and all-cause mortality.

2 | RESEARCH DESIGN AND METHODS

2.1 | Study design and population

ADVANCE was a 2 × 2 factorial RCT evaluating the effects of blood pressure-lowering (perindopril-indapamide combination vs. placebo) and intensive blood glucose-lowering (HbA1c ≤ 6.5% vs. standard glucose control) treatment on vascular outcomes in 11,140 individuals with T2D aged 55 years or older at high risk of cardiovascular events recruited in 20 countries.[6] All participants provided written informed consent.

2.2 | Study outcomes and follow-up

The primary outcome for this study was the composite of major macrovascular events (myocardial infarction, stroke or other cardiovascular death), new or worsening nephropathy (defined as new-onset macroalbuminuria, end-stage kidney disease, renal death and doubling of creatinine to >200 μmol/L) and all-cause mortality. Secondary outcomes were the individual components. Participants were followed from their 2-year visit until the earliest of the first study event, death or the end of follow-up (median 5 years; Figure S1).

2.3 | Statistical methods

Participants with serum creatinine measurements at 4, 12 and 24 months after randomization were eligible for inclusion into the current study. Patients with study outcomes during the first 2 years; those with missing serum creatinine or covariate information were excluded.

To account for known acute increases in serum creatinine following initiation of angiotensin-converting enzyme inhibitors,[9,10] we excluded the serum creatinine measurement obtained during the first 4 months. We therefore assessed eGFR[11] variability over a 20-month period based on serum creatinine measurements obtained at 4, 12 and 24 months after randomization. Variability in eGFR was assessed using the coefficient of variation (CV$_{eGFR}$). Participants were then grouped by thirds of CV$_{eGFR}$ (presented as a percentage) defined as: low (≤6.4; reference group), moderate (>6.4 to ≤12.1) and high (>12.1) variability. We also assessed variability as a continuous variable using restricted cubic spline regression models.

Log-linear trends across CV$_{eGFR}$ categories at baseline were tested by linear regression analysis and logistic regression analysis, as appropriate. Cox regression models were used to estimate hazard ratios (HRs), and their corresponding 95% confidence intervals (CIs), for eGFR variability adjusting for baseline participant characteristics (see Figure 1 for the full list).

We conducted sensitivity analysis, in which we repeated analyses (a) adjusting Cox models for eGFR slope at 24 months after randomization (estimated based on the same three eGFR measurements over the 20-month period using linear mixed models) and both baseline eGFR and eGFR slope; and (b) using two alternative indices of eGFR variability: standard deviation (SD; SD$_{eGFR}$) and range (range$_{eGFR}$).

Statistical analyses were performed with Stata software (release 16.1; StataCorp, College Station, TX, USA). A two-sided p-value less than .05 was considered statistically significant.

2.4 | Data availability

Restrictions apply to the availability of these data, which were used by agreement of the ADVANCE steering committee for the current study, and so are not publicly available.

Variability in eGFR (CV$_{eGFR}$)	N events/N total		p for trend	HR (95% CI)
Combined major macrovascular, new or worsening nephropathy and all-cause mortality (932 events)				
Low variability (reference)	262/2747			1.00 (Reference)
Moderate variability	306/2747		.015	1.07 (0.91–1.27)
High variability	364/2747			1.22 (1.03–1.45)
Major macrovascular events (466 events)				
Low variability (reference)	139/2747			1.00 (reference)
Moderate variability	165/2747		.649	1.10 (0.87–1.38)
High variability	162/2747			1.05 (0.83–1.34)
New or worsening nephropathy (296 events)				
Low variability (reference)	70/2747			1.00 (reference)
Moderate variability	84/2747		.009	1.07 (0.77–1.48)
High variability	142/2747			1.45 (1.07–1.97)
All-cause mortality (418 events)				
Low variability (reference)	115/2747			1.00 (reference)
Moderate variability	146/2747		.095	1.13 (0.88–1.45)
High variability	157/2747			1.24 (0.96–1.60)

0.8   1   1.5   2
HR (95% CI)

FIGURE 1 The association between levels of eGFR variability (coefficient of variation [CV]; CV$_{eGFR}$) and clinical outcomes. Variability is defined as: (1) low variability: CV$_{eGFR}$ ≤ 6.4 (reference); (2) moderate variability: CV$_{eGFR}$ > 6.4 to ≤12.1; and (3) high variability: CV$_{eGFR}$ > 12.1; models were adjusted for age*, sex, randomized blood pressure-lowering intervention, randomized glucose control intervention, region of residence, duration of diabetes*, history of macrovascular diseases*, smoking habit*, drinking habit*, body mass index*, angiotensin-converting enzyme (ACE) inhibitor use*, HbA1c*, total cholesterol*, low-density lipoprotein (LDL) cholesterol*, high-density lipoprotein (HDL) cholesterol*, log-transformed triglyceride*, estimated glomerular filtration rate* (eGFR), systolic blood pressure* (BP), log-transformed urine albumin-to-creatinine ratio* (UACR) and variability of systolic BP; participant characteristics were assessed at the 24-month study visit, where available (*indicates that characteristics were assessed at the 24-month visit). Models were adjusted for participant characteristics assessed at the 24-month study visit (after randomization), where available (including eGFR); otherwise, values assessed at study registration were used

3 | RESULTS

Of the 11,140 participants in the ADVANCE trial, 8241 participants (73.9%) were eligible for inclusion in the current study (Figure S1). The mean age of the cohort was 68.1 (SD 6.3) years, 43% were female and the mean duration of diabetes was 8.2 (interquartile interval [IQI]: 5.0–13.1) years at baseline (Table 1).

3.1 | Variability in eGFR in the first 20 months

Among patients with an eGFR of 60 mL/min/1.73m^2 or higher at the time of the first eGFR measurement (n = 6239), 35.7% (n = 2229), 34.3% (n = 2142) and 29.9% (n = 1868) experienced low, moderate and high variability over the following 20 months, respectively. Conversely, in those with an eGFR of less than 60 mL/min/1.73m^2 at the time of the first eGFR measurement (n = 2002), the corresponding figures were 25.9% (n = 518), 30.2% (n = 605) and 43.9% (n = 879), respectively. The overall median CV$_{eGFR}$, SD$_{eGFR}$ and range$_{eGFR}$ were 8.9 (IQI: 5.1–14.6), 6.2 (IQI: 3.5–10.0) mL/min/1.73m^2 and 11.6 (IQI: 6.6–19.2) mL/min/1.73m^2, respectively (Figure S2). The proportions of people with an eGFR of less than 60 mL/min/1.73m^2 (n = 2002) were higher in the high (43.9%) and moderate (30.2%) CV$_{eGFR}$ variability groups compared with the low variability group (25.9%). However, similar patterns

were not observed when participants were grouped according to tertiles of SD$_{eGFR}$ (29.3%, 31.4% and 39.3%, respectively) and range$_{eGFR}$ (29.2%, 31.8%, 39.0%, respectively; Table S1).

3.2 | Clinical events during further follow-up

During a median 2.9 (IQI: 2.5–3.0) years following the 20-month period in which eGFR variability was measured, 932 patients (11.3%) developed the primary composite outcome. There were 466 major macrovascular events (5.6%), 296 new or worsening nephropathy events (3.5%) and 418 deaths (5.0%). Overall, greater eGFR variability, assessed by the CV$_{eGFR}$, over 20 months was independently associated with a higher risk of the primary outcome (HR for moderate and high variability compared with low variability: 1.07, 95% CI: 0.91–1.27 and 1.22, 95% CI: 1.03–1.45, respectively; Figure 1) with evidence of a positive log-linear trend (p = .015).

Results for new or worsening nephropathy were consistent with those for the primary outcome (HR for moderate and high variability compared with low variability: 1.07, 95% CI: 0.77–1.48 and 1.45, 95% CI: 1.07–1.97, respectively; Figure 1). We did not observe statistically significant associations between greater eGFR variability and the risk of major macrovascular events or all-cause mortality. However, the overall direction of the associations was similar compared with those

TABLE 1 Characteristics of study participants by estimated glomerular filtration rate (eGFR) variability (thirds of eGFR coefficient of variation [CV]; CV_{eGFR})

Variable	Thirds of CV_{eGFR} (mL/min/1.73m²)			p for trend
	Low variability (≤6.4)	Moderate variability (>6.4 to ≤12.1)	High variability (>12.1)	
Number of participants	2747	2747	2747	
Demographic factors				
Age (years)	67.9 (6.4)	68.3 (6.2)	67.9 (6.2)	.758
Female (%)	1042 (38)	1107 (40)	1426 (52)	<.001
Residence in Asia (%)	970 (35)	943 (34)	1419 (52)	<.001
Medical and lifestyle history				
Duration of diabetes (years)	8.1 (4.2–13.1)	9.1 (5.1–13.2)	9.1 (5.1–13.2)	.001
History of macrovascular disease at baseline (%)	809 (29)	860 (31)	887 (32)	.023
Current smoking (%)	354 (13)	256 (9)	200 (7)	<.001
Current alcohol drinking (%)	868 (32)	802 (29)	528 (19)	<.001
ACE inhibitor use (%)	1449 (53)	1421 (52)	1368 (50)	.029
ADVANCE randomization: perindopril-indapamide	1281 (47)	1405 (51)	1430 (52)	<.001
ADVANCE randomization: intensive blood glucose control	1424 (52)	1367 (50)	1434 (52)	.787
Risk factors				
SBP (mmHg)	138 (18)	137 (18)	136 (18)	.077
DBP (mmHg)	77 (10)	77 (10)	76 (10)	.001
Body mass index (kg/m²)	28.2 (5.2)	28.4 (5.1)	27.9 (5.1)	.011
HbA1c (%)	6.9 (1.2)	6.9 (1.1)	6.9 (1.3)	.300
Total cholesterol (mmol/L)	4.8 (1.0)	4.8 (1.1)	5.0 (1.1)	<.001
Triglycerides (mmol/L)	1.5 (1.1–2.1)	1.6 (1.1–2.2)	1.6 (1.2–2.3)	<.001
UACR (µg/mg)	13.3 (6.5–32)	14 (6.8–33)	15.7 (7.8–42.4)	.001
CV_{SBP} (mmHg)	29.9 (4.7)	30.1 (4.8)	30.1 (4.8)	.033
First eGFR (mL/min/1.73m²) measurement[a]	76.7 (16.6)	71.7 (15.3)	69.5 (17.7)	<.001
Last eGFR (ml/min/1.73m²) measurement[a]	76.3 (16.5)	71.1 (15.8)	67.6 (18.8)	<.001
Mean rate of eGFR change (ml/min/1.73m²) over 20 mo (SD)	−0.19 (2.2)	−0.33 (4.9)	−0.97 (10.7)	<.001

Abbreviations: ACE, angiotensin-converting enzyme; DBP, diastolic blood pressure; SBP, systolic blood pressure.
Mean values and their corresponding standard deviations (SDs) are presented for continuous variables unless described otherwise; *median values (interquartile interval [IQI[) are presented for triglycerides and urine albumin-creatinine-ratio (UACR), categorical variables are presented as numbers and percentages (n, %).
[a]Assessed during the 24-month eGFR variability assessment period.

observed for the primary outcome and new or worsening nephropathy.

An evaluation of the relationship between continuous CV_{eGFR} and the risk of study outcomes showed similar associations for the primary and secondary outcomes (Figure S3).

Additional sensitivity analysis, in which (a) models were adjusted for eGFR slope (HR for primary outcome for moderate and high variability vs. low variability: 1.14, 95% CI: 0.96–1.34 and 1.36, 95% CI: 1.16–1.61, respectively; Figure S4), (b) models were adjusted for both baseline eGFR and eGFR slope (HR 1.07, 95% CI: 0.91–1.27 and 1.23, 95% CI: 1.04–1.45, respectively; Figure S5), and (c) eGFR variability was defined using SD_{eGFR} (HR 1.11, 95% CI: 0.95–1.31 and 1.22, 95% CI: 1.04–1.44, respectively; Figure S6) and $range_{eGFR}$ (HR 1.13, 95% CI: 0.96–1.32 and 1.22, 95% CI: 1.03–1.44, respectively; Figure S7), showed similar results.

4 | DISCUSSION

In this analysis of 8241 patients with T2D, greater variability in eGFR over 20 months predicted a higher risk of major clinical outcomes with evidence of a positive linear trend. Much of the association was driven by a higher risk of new or worsening nephropathy among those who experienced greater magnitudes of eGFR variability. Similar statistically significant associations were not observed for the major macrovascular events and all-cause death, although the direction of the association remained consistent. Overall findings were consistently observed when eGFR variability was defined using alternative measures including standard deviation and range, or when models were adjusted for baseline eGFR and eGFR slope. Our results suggest that greater eGFR variability may increase the future risk of clinically important outcomes in people with T2D.

Few studies have assessed the relationships between eGFR variability and clinical outcomes. The study conducted by Al-Aly et al.[4] reported a significantly increased risk of death associated with high eGFR variability in a cohort of 51,304 US veterans with reduced eGFR (HR 1.34, 95% CI: 1.28–1.40). In another smaller study of 2869 patients with CKD in Japan, greater eGFR variability was associated with a higher risk of cardiovascular events (HR for highest vs. lowest tertile of eGFR variability: 1.90, 95% CI: 1.03–3.71).[12] Our results further expand on these studies by showing a positive linear association between eGFR variability and a range of clinically relevant outcomes in people with T2D.

Greater within-person eGFR variability observed in the outpatient setting (i.e. variability not related to acute insults in kidney function) may be attributable to (a) deteriorating capacity to maintain renal homeostasis induced by progressive kidney function loss (i.e. an indicator of eGFR decline), and/or (b) external factors (e.g. medication use) that contribute to more random fluctuations that may not necessarily be associated with any discernible trends in eGFR trajectory. Our results showed that even after accounting for both baseline eGFR and eGFR slope (i.e. potential causative factors that may explain greater eGFR variability), greater eGFR variability predicted an increased risk of major clinical outcomes in T2D, that is, greater eGFR variability in people with T2D may have meaningful prognostic utility independent of baseline eGFR, including those in whom progressive eGFR decline is absent. Indeed, it has been postulated that loss of physiological homeostasis contributes to variability in a number of other measures such as blood pressure,[13–15] which in turn drives the increased risk of poor outcomes including cardiovascular disease and microvascular complications. Of note, while the mechanism through which this increased risk is driven may be similar to that postulated for the relationship between blood pressure variability and outcomes, our analyses accounted for blood pressure variability, suggesting that eGFR variability predicts changes in risk independent of blood pressure variability.

The strengths of our study include the assessment of the relationship between eGFR variability and clinically important outcomes based on multiple approaches and the large and diverse participant population derived from an international, multicentre RCT. Our study, however, has limitations. We used eGFR (instead of direct GFR measurement), which itself is subject to variation because of analytical error associated with creatinine measurement. It is possible that this may have led to some misclassification of eGFR variability. New or worsening nephropathy consisted mostly of new-onset macroalbuminuria (81%) and thus we were limited in our ability to assess the impact of eGFR variability on longer-term kidney outcomes. We assessed eGFR variability within the setting of a RCT and therefore the results may have limited generalizability to broader populations in more routine clinical settings.

In conclusion, greater variability in eGFR over 20 months predicted a higher risk of major clinical outcomes. Our results suggest that greater variability in eGFR, over and above single values of eGFR, may increase the future risk of clinically important outcomes in people

with T2D and that it may be an important prognostic marker in this population.

CONFLICT OF INTEREST

MJ reports receiving grant support from the NHMRC and unrestricted grant support from VentureWise (a wholly owned commercial subsidiary of NPS MedicineWise) to conduct a commissioned project funded by AstraZeneca, outside the submitted work. SVB has received speaker honoraria from Amgen, Bayer and Pfizer and has served on the advisory boards of Bayer and AstraZeneca. MW reports consultancy fees from Amgen, Kirin and Freeline outside the submitted work and grants from the NHMRC. JC received research grants from NHMRC and from Servier for the ADVANCE trial, and honoraria for speaking about these studies at scientific meetings.

HJLH has served as a consultant for Abbvie, AstraZeneca, Boehringer Ingelheim, Chinook, Dimerix, Janssen, Merck, MundiPharma and Mitsubishi-Tanabe, Retrophin, and has received grant support from Abbvie, AstraZeneca, Boehringer Ingelheim and Janssen. SH reports grants from the George Institute for International Health, during the conduct of the study; and other from Servier, outside the submitted work. PH reports consulting fees from Servier, grant support from Quebec CQDM and Servier. NP received honoraria and personal fees from Servier Laboratories, Takeda Pharmaceutical Company, Menarini Group and Pfizer, and grant support from Servier Laboratories and Pfizer. MG reports receiving honoraria from Shire and Amgen for speaking at scientific meetings. MJJ is responsible for research projects that have received unrestricted funding from Amgen, Baxter, CSL, Eli Lilly, Gambro and MSD, has served on advisory boards and steering committees sponsored by Akebia, Astra Zeneca, Baxter, Bayer, Boehringer Ingelheim, CSL, Janssen, MSD and Vifor, and has spoken at scientific meetings sponsored by Amgen, Janssen, Roche and Vifor, with any consultancy, honoraria or travel support paid to her institution. VP reports receiving advisory board, steering committee and/or lecture fees from AbbVie, Astellas, Baxter, Eli Lilly, Boehringer Ingelheim, Astellas, AstraZeneca, Janssen, Mitsubishi Tanabe, Merck, Mundipharma, Novo Nordisk and GlaxoSmithKline. All other authors report no conflicts of interest.

AUTHOR CONTRIBUTIONS

MJ, JC, VP and MW contributed to the concept and rationale for the study and interpretation of the results. MJ conducted statistical analysis and drafted the manuscript with advice from MW. All authors contributed to discussion and reviewed and edited the manuscript. MJ and MW are the guarantors of this work and, as such, had full access

to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

PEER REVIEW

The peer review history for this article is available at https://publons.com/publon/10.1111/dom.14351.

DATA AVAILABILITY STATEMENT

Restrictions apply to the availability of these data, which were used by agreement of the ADVANCE steering committee for the current study, and so are not publicly available.

ORCID

Min Jun https://orcid.org/0000-0003-1460-7535
Hiddo J. L. Heerspink https://orcid.org/0000-0002-3126-3730
Mark Woodward https://orcid.org/0000-0001-9800-5296

REFERENCES

1. Reutens AT. Epidemiology of diabetic kidney disease. *Med Clin North Am.* 2013;97:1-18.
2. Fox CS, Matsushita K, Woodward M, et al. Chronic kidney disease prognosis consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. *Lancet.* 2012;380:1662-1673.
3. Kidney Disease Improving Global Outcomes (KDIGO). KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int.* 2012;3(suppl):1-150.
4. Al-Aly Z, Balasubramanian S, McDonald JR, Scherrer JF, O'Hare AM. Greater variability in kidney function is associated with an increased risk of death. *Kidney Int.* 2012;82:1208-1214.
5. Tseng CL, Lafrance JP, Lu SE, et al. Variability in estimated glomerular filtration rate values is a risk factor in chronic kidney disease progression among patients with diabetes. *BMC Nephrol.* 2015;16:34.
6. ADVANCE Management Committee. Study rationale and design of ADVANCE: action in diabetes and vascular disease—preterax and diamicron MR controlled evaluation. *Diabetologia.* 2001;44:1118-1120.
7. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet.* 2007;370:829-840.
8. ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *N Engl J Med.* 2008;358:2560-2572.
9. KDIGO. Clinical practice guideline for the Management of Blood Pressure in chronic kidney disease. *Kidney Int Suppl.* 2012;2: 337-414.
10. Ohkuma T, Jun M, Rodgers A, et al. Acute increases in serum creatinine after starting angiotensin-converting enzyme inhibitor-based therapy and effects of its continuation on major clinical outcomes in type 2 diabetes mellitus. *Hypertension.* 2019;73:84-91.
11. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. *Ann Intern Med.* 2009;150:604-612.
12. Suzuki A, Obi Y, Hayashi T, et al. Visit-to-visit variability in estimated glomerular filtration rate predicts hospitalization and death due to cardiovascular events. *Clin Exp Nephrol.* 2019;23:661-668.
13. Kim MK, Han K, Park YM, et al. Associations of variability in blood pressure, glucose and cholesterol concentrations, and body mass index with mortality and cardiovascular outcomes in the general population. *Circulation.* 2018;138:2627-2637.
14. Hata J, Arima H, Rothwell PM, et al. Effects of visit-to-visit variability in systolic blood pressure on macrovascular and microvascular complications in patients with type 2 diabetes mellitus: the ADVANCE trial. *Circulation.* 2013;128:1325-1334.
15. Dorajoo SR, Ng JSL, Goh LHF, et al. HbA1c variability in type 2 diabetes is associated with the occurrence of new-onset albuminuria within three years. *Diabetes Res Clin Pract.* 2017;128:32-39.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of this article.